The gastroesophageal cancer market—including gastric cancer, esophageal adenocarcinoma and gastroesophageal junction (GEJ) adenocarcinoma—is witnessing a substantial change, largely fueled by label expansions of immune checkpoint inhibitor therapies. The PD-1 inhibitor Opdivo (Bristol Myers Squibb) expanded its label in the United States to esophageal cancer patients and is under regulatory review, along with Keytruda (Merck & Co.), for first-line and resectable gastroesophageal cancer populations. The approval of the HER2 antibody-drug conjugate Enhertu (Daiichi Sankyo / AstraZeneca) has also expanded the treatment options for HER2-positive patients. Given the intense Phase II/III pipeline activity, we anticipate the approval of several new therapies for gastroesophageal cancer during the forecast period.
Disease Landscape & Forecast provides comprehensive market intelligence with world-class epidemiology, keen insight into current treatment paradigms, in-depth pipeline assessments, and drug forecasts supported by detailed primary and secondary research.
Disease Landscape & Forecast will feature continuous updates in 2021 to provide timely insights and analyses as meaningful indication-specific news and events unfold.